Vertex Pharmaceuticals
VRTX
1,277 hedge funds and large institutions have $81.9B invested in Vertex Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 84 funds opening new positions, 533 increasing their positions, 459 reducing their positions, and 77 closing their positions.
16% more repeat investments, than reductions
Existing positions increased: 533 | Existing positions reduced: 459
9% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 77
6% more call options, than puts
Call options by funds: $674M | Put options by funds: $633M
1% less funds holding
Funds holding: 1,285 → 1,277 (-8)
0.97% less ownership
Funds ownership: 92.34% → 91.37% (-0.97%)
2% less capital invested
Capital invested by funds: $83.3B → $81.9B (-$1.4B)
6% less funds holding in top 10
Funds holding in top 10: 33 → 31 (-2)
Top Buyers
Top Sellers
VRTX Hedge Fund Activity: Q3 2023 in Review
1,277 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q3 2023, worth a combined $81.9B — down 1.7% from $83.3B a quarter earlier.
Buyers outnumbered sellers: 84 funds opened new VRTX positions and 77 closed out — a net gain of 7 holders — while 533 added to existing stakes and 459 trimmed.
The largest buyer was Capital World Investors, adding an estimated $224M. The largest seller was Wellington Management Group, cutting an estimated $359M.
- 1,277 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q3 2023, down from 1,285 in Q2 2023.
- Funds reported $81.9B of Vertex Pharmaceuticals stock for Q3 2023, down 1.7% quarter-over-quarter.
- 84 funds opened new Vertex Pharmaceuticals positions in Q3 2023 and 77 closed out, a net change of +7 holders.
- The largest Vertex Pharmaceuticals buyer in Q3 2023 was Capital World Investors, an estimated $224M added.
- The largest Vertex Pharmaceuticals seller in Q3 2023 was Wellington Management Group, an estimated $359M sold.
Based on aggregated 13F filings for Q3 2023.